Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in
which IMT-009 will be administered by the intravenous (IV) route to participants with solid
tumors or lymphomas.
The main goals of this study are to:
- Find the recommended dose of IMT-009 that can be safely given to participants
- Learn more about the side effects of IMT-009
- Learn more about pharmacokinetics of IMT-009
- Learn more about the effectiveness of IMT-009
- Learn more about different pharmacokinetic biomarkers and how they might change in the
presence of IMT-009